BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Business

  Biogen, Inc. Appoints Kenneth DiPietro Executive Vice President, Human Resources

  January 30, 2012

   · 

  1 min read
• Genetown

  Alnylam Pharmaceuticals Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) for Systemic Delivery of RNAi Therapeutics

  January 30, 2012

   · 

  1 min read
• BioMidwest

  Omnicare, Inc. Comments on Federal Trade Commission Position

  January 30, 2012

   · 

  1 min read
• Business

  KineMed, Inc. Announces Research Collaboration with Pfizer Inc. for the Advancement of Novel Approaches in Metabolic Disease

  January 30, 2012

   · 

  2 min read
• Policy

  PharMerica Comments on Federal Trade Commission Decision to Block Omnicare, Inc.’s Hostile Tender Offer

  January 30, 2012

   · 

  1 min read
• Drug Development

  AMAG Pharmaceuticals, Inc. Announces Completion of Enrollment in its Phase III Program Evaluating Feraheme for a Broader Iron Deficiency Anemia Indication

  January 30, 2012

   · 

  1 min read
• Business

  Saladax Biomedical Inc. (SBI) Announces the Resignation of Edward L. Erickson as President and Chief Executive Officer

  January 30, 2012

   · 

  2 min read
• Drug Development

  Allos Therapeutics, Inc. Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at theEuropean Medicines Evaluation Agency

  January 30, 2012

   · 

  1 min read
• FDA

  CardioKinetix Inc. Receives Expanded CE Mark Approval for World’s First Percutaneous Left Ventricular Partitioning Device, the Parachute(TM), for Treatment of Ischemic Heart Failure

  January 30, 2012

   · 

  3 min read
• Drug Development

  Rock Creek Pharmaceuticals Reports First Clinical Trial Showing Anatabloc(TM) Lowers Chronic Inflammation Measured by CRP Blood Levels in Humans

  January 30, 2012

   · 

  5 min read